The rise of individualized medicine is the new direction in oncology. More sophisticated and complex testing will be required to select the right therapy for the right patient at the right time in their treatment. Clarient has created a state-of-the-art commercial cancer laboratory providing the most advanced oncology testing and diagnostic services available both onsite and over the web. The Company is also developing new, proprietary “companion” diagnostic markers for therapeutics in breast, prostate, lung and colon cancers, and leukemia/lymphoma. Clarient has over 1,700 targeted cancer therapeutics in their pipeline.

Todd S. Barry, M.D., Ph.D. has joined Clarient’s medical staff as Medical Director. Dr. Barry was the Director of Molecular Pathology & Hematopathology for six years at PhenoPath Laboratories, PLLC, a national reference laboratory located in Seattle. Prior to that, he did his Fellowship Training in Hematopathology at the National Cancer Institute. He has also published numerous professional studies and is a frequent presenter at pathology conferences.

Ron Andrews, Clarient’s Chief Executive Officer commented, “Central to successful execution of personalized medicine is the convergence of molecular pathology and oncology, and Dr. Barry’s experience will clearly add significant value to Clarient’s efforts to fulfill the promise of this emerging market opportunity.”

Let us hear your thoughts below:

Last 5 posts by QualityStocks

• Some Options as the US Dollar Continues its Slide - November 24th, 2009
• Newport Digital Technologies (NPDT.OB) Has a Competitive Edge - November 24th, 2009
• Small Cap Voice Featured Company: DecisionPoint Systems, Inc. (DNPI.OB) - November 24th, 2009
• Small Cap Voice Featured Company: Hitor Group, Inc. (HITR.OB) - November 24th, 2009
• Novavax, Inc. (NVAX) Prices Offering Of Common Stock - November 24th, 2009